Open AccessVaccine Delivery: Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8 + T Cell Responses (Adv. Sci. 1/2018)
Author(s) -
Jiang Hao,
Wang Qin,
Li Lin,
Zeng Qin,
Li Hanmei,
Gong Tao,
Zhang Zhirong,
Sun Xun
Publication year - 2018
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.201870001
Subject(s) - adjuvant , lymph node , antigen , nanoparticle , cd8 , vaccination , lymph , alum , medicine , nanotechnology , cancer research , chemistry , immunology , materials science , pathology , organic chemistry
Alum, the well‐known vaccine adjuvant with a long history of clinical use, is changed from a “gel” to nanoparticles. This changes its mechanism of action from a “depot” that resides at the injection site, to nanoparticles that transport antigen and adjuvant into the lymph node. As reported by Xun Sun and co‐workers in article number 1700426 , this lymph node targeting strategy significantly improves the efficacy of vaccinations and offers a potential nanovaccine platform for treating cancer and other diseases.